Modeyso is the first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma, targeting both adult and pediatric patients. Clinical trials demonstrated a 22% overall response rate with ...
Midline catheters and vascular access devices (VADs) play a pivotal role in modern clinical practice by offering less invasive alternatives to central venous access. Midline catheters, which are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback